Also known as: Orphan drug designation, Rare disease drug, Orphan product, ODD
Key facts
- Legal basis
- Orphan Drug Act of 1983; FDA regulations at 21 CFR Part 316
- Rare disease threshold
- Fewer than 200,000 people in the U.S., or no expected cost recovery
- Administered by
- FDA Office of Orphan Products Development
- Marketing exclusivity
- 7 years for the approved orphan indication
- Other incentives
- Clinical testing tax credit and a user fee waiver for orphan applications
What is an orphan drug?
Orphan status is a designation, not an approval. A sponsor requests orphan drug designation for a specific drug and a specific rare disease, often early in development, and the FDA grants it when the prevalence criterion and a plausible scientific rationale are met.
One drug can hold several orphan designations for different diseases, and a drug approved for a common condition can also carry an orphan designation for a rare one. The FDA records designations and orphan approvals separately in its public orphan designation database.
An alternative criterion covers diseases affecting more people when there is no reasonable expectation that U.S. sales will recover development costs, but it is rarely used.
How orphan drug incentives work
Designation unlocks several incentives, and approval for the designated use adds exclusivity:
- Orphan drug exclusivity: for 7 years after approval, the FDA cannot approve the same drug for the same rare disease use, unless a later product is clinically superior or the sponsor cannot supply enough.
- Tax credit: sponsors can claim a federal credit for qualified clinical testing costs; the Tax Cuts and Jobs Act of 2017 reduced the rate from 50 percent to 25 percent.
- User fee waiver: applications for a product designated for a rare disease are exempt from the prescription drug user fee application fee, subject to conditions.
- Grants: the FDA Orphan Products Grants Program funds clinical studies of rare disease products.
Why orphan drug status matters
Orphan status changes competitive timelines and pricing rules:
- Exclusivity modeling: orphan exclusivity can block a competing version for the protected indication after other protections lapse, although competitors may still seek unprotected indications.
- Medicare price negotiation: the Inflation Reduction Act excludes certain orphan drugs from negotiation, and Congress broadened that exclusion in 2025 to cover drugs approved only for one or more rare diseases.
- 340B pricing: the 340B Drug Pricing Program excludes orphan drugs from required discounts for some hospital types, such as critical access hospitals and rural referral centers, and the scope of that exclusion has been litigated.
- Pipeline analysis: orphan designations are public and dated, so they are an early signal of rare disease programs years before approval.